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The immunoregulatory polypcptide prothymosin ct and its biologically active N-terminal fragment thymosin 
cqm, with relative molecular masses of 12 500 and 3108 respectively, were found to behave as oligomers 
(trimers to hexamers) in gel-filtration measurements. This phenomenon f an apparent association of poly- 
peptides has been reported for other thymosins - parathymosin ~t,thymosin f14 and thymosin ill0. In contrast, 
sedimentation equilibrium ultracentrifugation shows that thymosin cq is a monomer with a relative molecu- 
lar mass of 3000___200. Measurement of the diffusion coefficient as 221 gm2/s suggests that the molecule 
is approximately spherical. The implications for the molecular species of prothymosin ~, parathymosin ct,
and fl-thymosins are discussed. 
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1. INTRQDUCTION 
Thymosins are peptides affecting the differentia- 
tion and maturation of T-cells (review [1]). The 
first members of or- and ~'-thymosins isolated from 
thymosin fraction 5 (fS) - a complex extract of calf 
thymus [2] - were the 28-residue thymosin t~1 [3] 
and the 43-residue thymosin B4 [4]. 
Later, new members were added to the or- and fl- 
thymosin families (fig.l), namely thymosins 
des(25-28)-crl and or11, consisting of the thymosin 
crl sequence minus 4 and plus 7 amino acid residues 
respectively at the C-terminus [5]; prothymosin or, 
approx. 113 residues in length and the natural 
precursor, from which thymosin ~rl and its related 
short peptides are derived by proteolytic degrada- 
tion during the preparation of f5 [6,7]; para- 
thymosin or, a polypeptide of approx. 105 residues 
and partly homologous with prothymosin cr [8,9]; 
thymosins Ha and ill0, the 41- and 42-residue pep- 
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tides found to accompany thymosin ~4 in mam- 
malian tissues [10,11]; thymosin ~8, apparently 
another artifact from fS, as it is identical to 
thymosin ~'9 with two residues removed [10]; and 
thymosin ~'11 isolated from trout tissues [12]. 
Thymosin a,1 has been reported to: modulate the 
levels of terminal deoxynucleotidyl transferase ac- 
tivity in lymphocytes [13]; stimulate the produc- 
tion of macrophage inhibition factor [14] and 
interferon [15]; and increase the percentage of 
glucocorticoid-resistant lymphocytes [16]. Thymo- 
sin an was also found to increase the expression 
of interleukin-2 receptors in normal human lym- 
phocytes [17]. In vivo, thymosin t~l has been 
reported to protect sensitive or immunosuppressed 
mice against opportunistic infections [5,18,19]; to 
cooperate with interferon in boosting natural killer 
activity in immunosuppressed animals [20]; and in 
lung cancer patients, immunosuppressed by radio- 
therapy, to raise percentages of helper T-cells and 
improve relapse-free and general survival [21]. 
Thymosin ¢~11 was found to be equally potent to 
thymosin a,~ in enhancing the resistance of suscep- 
tible mice to challenge with Candida albicans [5], 
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Fig. 1. The primary structures of oe- and ~-thymosins. Amino acid sequences are shown using the single-letter code. 
Homologous regions are enclosed in dashed boxes. A deletion has been assumed between residues 27 and 28 of 
parathymosin o~for maximum homology. The sequences of prothymosin tr and parathymosin oe beyond residue 44 are 
not shown. Similar residues (identical, or conservative substitutions) for the oe- and fl-thymosins given in table 1 are 
underlined. 
while prothymosin oe was found to be active at 
doses significantly lower (1/20 or 1/30 on a molar 
basis) than those required for the shorter peptides 
[8]. In the same test, parathymosin oe exhibited 
much weaker activity, but when administered to- 
gether with prothymosin crit appeared to block the 
immunoenhancing effect of the latter [8]. 
Thymosin f14 has been reported to" induce ter- 
minal deoxynucleotidyl transferase activity in bone 
marrow cells from normal and athymic mice in 
vivo [4] and in vitro [22]; inhibit the migration of 
guinea pig peritoneal macrophages [14], possibly 
acting directly on these cells [23]; and stimulate the 
hypothalamic secretion of luteinizing-hormone 
releasing factor from superfused medial basal 
hypothalami of female rats [24]. 
Recently, antisera raised against thymosin cn 
were found to inhibit replication, in cultured cells, 
of the AIDS-associated virus, HIV [25]. Cross- 
reactivity of the immune response, which may pro- 
vide a basis for preparing a vaccine against HIV, 
is supported by homology between thymosin trl 
and a section of p17, a protein product of the gag 
gene of the virus [25]. 
In view of the various biological properties in- 
voked for thymosins, it is of interest o establish 
the molecular entities that exist in solution as their 
functional units. Gel filtration under denaturing 
conditions (6 M guanidinium chloride on Sepha- 
dex G-75) confirmed the sizes of the polypeptides 
of thymosins ~1 and Z?4 [26]. However, gel filtra- 
tion without denaturants, on Sephacryl S-200, 
gave a relative molecular mass near 11 000 rather 
than 3100 for thymosin a,,, and 32000 rather than 
12 600 for prothymosin a, [6]. Parathymosin tr and 
thymosins f14 and ill0 also gave molecular sizes 
several fold higher than those calculated for single 
polypeptides [8]. These results suggested the for- 
mation in solution of oligomers of thymosins. The 
present investigation was undertaken to establish 
the size of the molecular species of thymosin in 
solution by sedimentation equilibrium analysis. 
Thymosin a~ was used because the synthetic pep- 
tide was the only thymosin available in sufficient 
quantity for these experiments. Furthermore, it is 
the smallest hymosin for which there was an in- 
dication of oligomer formation; its sequence is 
common with other tr-thymosins and corresponds 
to the N-terminal segment of prothymosin a~, and 
is that segment which has the highest degree of 
108 
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homology with parathymosin oe. Therefore, it 
should be anticipated that the physical properties 
found for thymosin aq would also be shown by 
these related polypeptides. 
2. MATERIALS AND METHODS 
Thymosin a'l was chemically synthesized [27], 
and rat prothymosin a~ [6] and thymosin/34 [281 
were isolated from thymus tissue. Sephacryl S-200 
was purchased from Pharmacia, Sweden. 
A phosphate buffer, pH 7.0, I=  0.1 + 0.2 M 
KC1 (2.79 g KH2PO4, 4.61 g K2HPO4 and 14.9 g 
KC1 in 1 1 solution) was used for gel-filtration and 
analytical ultracentrifugation experiments. Gel- 
filtration experiments were also performed in 1 M 
HCOOH-0.2 M pyridine buffer, pH 2.8, I=  0.2 
(38 ml formic acid and 14.4 ml pyridine per I solu- 
tion). 
Columns of Sephacryl S-200 (1.5 × 90 cm) 
equilibrated with buffer were calibrated using 
0.8 ml of 1.5°7o glycerol solution in phosphate buf- 
fer containing 5 mg of each of the following 
marker proteins: bovine serum albumin (67 kDa), 
ovalbumin (45 kDa), chymotrypsinogen A 
(25 kDa), ribonuclease (13.7 kDa) and aprotinin 
(6.5 kDa). Samples containing 6/~g thymosin cr~ 
and 20/zg prothymosin oe were applied to the same 
column, and the peptides were detected by radio- 
immunoassay [29]. The flow rate was 5.7 ml/h and 
1.14 ml fractions were collected. 
The sedimentation equilibrium experiments were 
carried out using a Beckman model E analytical 
ultracentrifuge, fitted with an RTIC unit. The 
temperature was maintained at 4°C, and the initial 
protein concentration was approx. 7 mg/ml. 
Before gel-filtration and ultracentrifugation ex- 
periments the lyophilized peptide was dissolved in 
phosphate buffer, pH 7.0, I = 0.1 + 0.2 M KCI. A 
value of 0.722 ml/g was used for the partial 
specific volume of thymosin tzl calculated [31] 
from the amino acid composition. Data on the 
densities of the salt solutions were taken from In- 
ternational Critical Tables. 
Weight-average and z-average molecular 
weights, Mw and Mz, were determined from 
sedimentation equilibrium experiments [30], using 
schlieren optics and solution columns of 3 mm. 
The initial concentration was determined in a 
separate synthetic boundary experiment and, 
assuming conservation of mass for a sector-shaped 
cell, numerical integration was used to give the 
distribution of concentration for the calculation of 
Mw [30]. Heterogeneity of preparations was 
detected by plots of log c vs r 2 and of (1/r. dc/dr) 
vs (Cr - Ca), where cr and Ca are the concentrations 
at radial distance, r, and at the meniscus, respec- 
tively. 
The diffusion coefficient was obtained by 
measuring the spreading of a synthetic boundary in 
a low centrifugal field [32], these experiments also 
being done at 4°C. 
3. RESULTS AND DISCUSSION 
Formate-pyridine buffer at pH 2.8 was used in- 
itially for gel filtration because, after separation, 
the samples were either directly subjected to 
reversed-phase HPLC, or else the volatile buffer 
components could be readily removed by 
lyophilization. Here, a pH near the physiological 
value was used. Gel filtration, on Sephacryl S-200, 
in phosphate buffer at pH 7 gave a relative 
molecular mass of 17000 for thymosin a~ and 
56 000 for prothymosin o~ (fig.2). These values are 
approx. 5-fold, rather than the 3-fold increases ob- 
tained in pyridine-formate buffers at pH 2.8 (table 
1), and apparently confirm the self-association f
thymosins. 
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Fig.2. Gel filtration on Sephacryl S-200. The graph 
shows the elution volumes of synthetic thymosin oei and 
rat prothymosin ot in relation to the marker proteins: 
bovine serum albumin (1); ovalbumin (2); chymotryp- 
sinogen A (3); ribonuclease (4); and aprotinin (5). The 
buffer was phosphate pH 7.0, I = 0.1 + 0.2 M KCI, and 
the temperature was 4°C. 
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Thymosin Mr (calculated) Mr (observed) Buffer a Ref. 
1.3 
Thymosin oe, 3 108 10 500 HCOOH/pyridine [6] 
Thymosin cr~ 3 108 17 000 phosphate fig.2 
Prothymosin ce 12 500 32 000 HCOOH/pyridine [6] 
Prothymosin ce 12 500 56 000 phosphate fig.2 
Parathymosin c~ 11 800 32 000 HCOOH/pyridine [8] 
Thymosin f14 4 963 17 000 HCOOH/pyridine [28] 
Thymosin fl~o 4 737 17 000 HCOOH/pyridine [28] 
a The HCOOH/pyridine buffer had a pH of 2.8, 1 0.2, and was used at 22°C, while the phosphate buffer had a pH 
of 7.0, 1 0.3, and was used at 4°C 
In contrast,  according to sedimentat ion 
equi l ibr ium ultracentr i fugat ion at pH 7.0 and 
I = 0.3, the Mw for thymosin or1 was 2800 and the 
Mz was 3200, close to the value of  3108 calculated 
from the amino acid sequence. The graph of  log c 
vs r 2, used for the calculat ion of  Mw, was l inear 
(fig.3), as was the graph of  (1/r. dc/dr) vs (Cr - ca) 
used for the calculat ion of  Mz (fig.4). Therefore,  
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Table 1 
Relative molecular masses for thymosins according to gel filtration 
Fig.3. Sedimentation equilibrium giving M,  for 
thymosin co. The graph shows the logarithm of concen- 
tration plotted vs the radial distance. The slope cor- 
responds to an M,  value of 2840. The buffer was 
phosphate, pH 7.0, I = 0.1 + 0.2 M KCI, at 4°C; rotor 
speed was 42040 rpm, and the duration of the experi- 
ment was 18 h. The concentration is in arbitrary units. 
under the above condit ions,  a discrete molecular  
species was found corresponding to the monomer.  
A l though the experiments were carried out at a pH 
far removed f rom the isoelectric point of  thymosin 
c~1, the problems of  non-ideal i ty that could arise 
from charge interactions were avoided by using a 
high ionic strength in the buffer.  Thus, under the 
present experimental  condit ions with a net charge 
of  -6  on the peptide (f ig. l ) ,  the ion imbalance 
,~ 0.1 
I n  
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0.1 0.2 
(c r -  Ca) 
Fig.4. Sedimentation equilibrium giving Mz for 
thymosin ce~. The graph shows the ratio of refractive in- 
dex increment to radial position plotted vs increase in 
concentration from the meniscus. The slope corresponds 
to an Mz value of 3200. Experimental conditions were as 
given for fig.3. The concentration is in arbitrary units. 
I I0  
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arising from the Donnan effect would be less than 
a factor of 1.03 [33]. 
An erroneously high molecular weight could be 
inferred from gel filtration of a highly asymmetric 
molecule. Accordingly, the diffusion coefficient of 
thymosin o<~ was measured in the same buffer, i.e. 
phosphate, pH 7, 0.3 I, and the D2o,w was found to 
be 221/zm2/s. Combining this value with a relative 
molecular mass of 3100 and partial specific volume 
of 0.722 ml/g, gives a frictional ratio of 1.01, in- 
dicating approximate spherical symmetry for the 
thymosin molecule. For comparison, ribonuclease 
with a relative molecular mass of 13 700 has a D20,w 
value of 122/zm3/s [30] and a diffusion coefficient 
lower than that of ribonuclease would be required 
to explain the relative lution volume on gel filtra- 
tion of thymosin try. 
In the absence of aggregation or asymmetry, 
anomalous behaviour on gel filtration may be 
caused by exclusion of thymosin from the gel by 
charge repulsion. This could arise from the occa- 
sional negative charges on the polysaccharide 
matrix preventing access to small pores by a high 
density of negative charges on the peptide. This 
property could explain the high apparent 
molecular weight for thymosin eel at pH 7, but not 
the apparent increase in size at pH 2.8 [6], since the 
carboxyl groups should be extensively protonated 
at low pH. Correspondence to the monomer of the 
molecular size in 6 M guanidinium chloride [26] 
suggests that, besides unfolding the peptide, the 
denaturant obscures any charge interactions by 
contributing a very high concentration of ions. 
Other proteins that are rich in acidic amino acids 
also give anomalously high molecular weights on 
gel filtration. These include calmodulin and 
troponin-C, which behave like molecules of 
relative mass 30000 on gel filtration rather than 
17000-18000 [34], and the chromosomal 'high- 
mobility group protein', HMG2, which gave a 
value of 45 000 rather than 29000 for its relative 
molecular mass [35]. The discrepancy in thymosin 
a,t is more pronounced, which may arise from the 
small size of the peptide and its correspondingly 
higher charge density. 
Since the sedimentation equilibrium experiments 
were carried out at a high concentration - 7 mg/ml 
or 2.2 mM of thymosin Crl - the peptide should be 
monomeric at the low concentrations that occur in 
vivo; for example, prothymosin ~ is present at a 
concentration of 400/zg/g or 0.03 mM in the rat 
thymus [28]. 
As the apparently high molecular size of 
thymosin a,~ seems to be an artifact of gel filtra- 
tion, the same consideration may well apply to the 
other thymosins that have been subjected to this 
technique. The high charge density of thymosin eel 
that could be responsible for its anomalous 
behaviour on gel filtration is present in the N- 
terminal segment of prothymosin ~, and a 
homologous sequence occurs at the N-terminus of 
parathymosin or. It is of interest hat the region 
near the N-terminus (and not the C-terminus) is 
conserved between rat and human prothymosins 
[36], which suggests that this segment is significant 
for its biological function. As trout prothymosin ce
also shows a high degree of aggregation according 
to gel filtration, with an apparent molecular weight 
of 55000 [1], it would be of interest o know 
whether the sequence near its N-terminus is 
homologous with the other prothymosins. 
Conversely, although the present observations 
show that thymosin ce~ is monomeric, there re- 
mains the possibility that in an extended polypep- 
tide, as in prothymosin c~, the surface profile may 
be modified to allow association. Further in- 
vestigations of the hydrodynamic properties of 
prothymosin o~, parathymosin ~, and the B- 
thymosins hould prove of importance in under- 
standing the functional behaviour of these 
regulators of T-cell proliferation. 
ACKNOWLEDGEMENTS 
This work was partly supported by the Greek 
Ministry of Industry, Energy and Technology, and 
by a travel grant to A.A.H. from the Royal Socie- 
ty, London. 
REFERENCES 
[1] Haritos, A.A. (1987) Curr. Top. Biol. Med. Res. 
14, in press. 
[2] Hooper, J.A., McDaniel, M.C., Thurman, G.B., 
Cohen, G.H., Schulof, R.S. and Goldstein, A.L. 
(1975) Ann. NY. Acad. Sci. 249, 125-144. 
[3] Goldstein, A.L., Low, T.L.K., McAdoo, M., 
McClure, J., Thurman, G.B., Rossio, J.L., Lai, 
C.-X., Chang, D., Wang, S.-S., Harvey, C., 
Ramel, A.H. and Meienhofer, J. (1977) Proc. Natl. 
Acad. Sci. USA 74, 725-729. 
II I 
Volume 218, number I FEBS LETTERS June 1987 
[4] Low, T.L.K., Hu, S. and Goldstein, A.L. (1981) 
Proc. Natl. Acad. Sci. USA 78, 1162-1166. 
[5] Caldarella, J., Goodall, G.J., Felix, A.M., 
Heimer, E.P., Salvin, S.E. and Horecker, B.L. 
(1983) Proc. Natl. Acad. Sci. USA 80, 7424-7427. 
[6] Haritos, A.A., Goodall, G.J. and Horecker, B.L. 
(1984) Proc. Natl. Acad. Sci. USA 81, 1008-1011. 
[7] Haritos, A.A., Blacher, R., Stein, S., Caldarella, J.
and Horecker, B.L. (1985) Proc. Natl. Acad. Sci. 
USA 82, 343-346. 
[8] Haritos, A.A., Salvin, S.B., Blacher, R., Stein, S. 
and Horecker, B.L. (1985) Proc. Natl. Acad. Sci. 
USA 82, 1050-1053. 
[9] Komiyama, T., Pan, L.X., Haritos, A.A., 
Wideman, J.W., Pan, Y.-C.E., Chang, M., 
Rogers, I. and Horecker, B.L. (1986) Proc. Natl. 
Acad. Sci. USA 83, 1242-1245. 
[10] Hannappel, E., Davoust, S. and Horecker, B.L. 
(1982) Proc. Natl. Acad. Sci. USA 79, 1708-1711. 
[11] Erickson-Viitanen, S., Ruggieri, S., Natalini, P. 
and Horecker, B.L. (1983) Arch. Biochem. Bio- 
phys. 225,407-413. 
[12] Erickson-Viitanen, S. and Horecker, B.L. (1984) 
Arch. Biochem. Biophys. 233, 815-820. 
[13] Hu, S.-K., Low, T.L.K. and Goldstein, A.L. 
(1981) Mol. Cell. Biochem. 41, 49-58. 
[14] Thurman, G.B., Low, T.L.K., Rossio, J.L. and 
Goldstein, A.L. (1981) in: Lymphokines and 
Thymic Hormones: Their Potential Utilization in 
Cancer Therapeutics (Goldstein, A.L. and 
Chirigos, M.A. eds) pp. 145-157, Raven, New 
York. 
[15] Huang, K., Kind, P.D., Jagoda, E.M. and 
Goldstein, A.L. (1981) J. Interferon Res. 1, 
411-420. 
[16] Osheroff, P.L. (1981) Cell. Immunol. 60, 376-385. 
[17] Sztein, B.M., Serrate, S.A. and Goldstein, A.L. 
(1986) Proc. Natl. Acad. Sci. USA 83, 6107-6111. 
[18] Bistoni, F., Marconi, P., Fratassar, E. and Garaci, 
E. (1982) Infect. Immun. 36, 609-614. 
[19] Ishitsuka, H., Umeda, Y., Sakamoto, A. and Yagi, 
Y. (1983) in: Biological Response Modifiers in 
Human Oncology and Immunology (Klein, T. et al. 
eds) pp. 89-100, Plenum, New York. 
[20] Favalli, C., Tezzi, T., Mastino, A., Rinaldi-Garaci, 
C., Riccardi, C. and Garaci, E. (1985) Cancer 
Immunol. Immunother. 20, 189-192. 
[21] Schulof, R.S., Lloyd, M.L., Cleary, P.A., 
Palaszynski, S.R., Maj, D.A,, Cox, J.W. jr, 
Alabaster, O. and Goldstein, A.L. (1985) J. Biol. 
Resp. Modif. 4, 147-158. 
[22] Pazmino, N.H., Ihle, J.N. and Goldstein, A.L. 
(1978) J. Exp. Med. 147, 708-718. 
[23] Low, T.L.K. and Goldstein, A.L. (1984) Thymus 
6, 27-42. 
[24] Rebar, R.W., Miyake, A., Low, T.L.K. and 
Goldstein, A.L. (1981) Science 214, 669-671. 
[25] Sarin, P.S., Sun, D.K., Thornton, A.H., Naylor, 
P.H. and Goldstein, A.L. (1986) Science 232, 
1135-1137, 
[26] Low, T.L.K. and Goldstein, A.L. (1985) Methods 
Enzymol. 116, 248-255. 
[27] Felix, A.M., Heimer, E.P., Wang, C.-T., 
Lambros, T.J., Swistok, J., Roszkowski, M., 
Ahmad, M., Confalone, D., Scott, J.W., Parker, 
D., Meienhofer, J., Trzeciak, A. and Gillessen, D. 
(1985) Int. J. Peptide Protein Res. 26, 130-148. 
[28] Haritos, A.A., Caldarella, J. and Horecker, B.L. 
(1985) Anal. Biochem. 144, 436-440. 
[29] Haritos, A.A. and Horecker, B.L. (1985) J. 
Immunol. Methods 81, 199-205. 
[30] Van Holde, K.E. and Baldwin, R.L. (1958) J. 
Phys. Chem. 62, 734-743. 
[31] Cohn, E.J. and Edsall, J.T. (1943) in: Proteins, 
Amino Acids and Peptides, Rheinhold, New York, 
p. 370. 
[32] Schachman, H.K. (1957) Methods Enzymol. 4, 
32-103. 
[331 Tanford, C. (1961) in: Physical Chemistry of 
Macromolecules, Wiley, New York, pp. 225-227. 
[34] Dedman, J.R., Potter, J.D., Jackson, R.L., 
Johnson, J.D. and Means, A.R. (1977) J. Biol. 
Chem. 252, 8415-8422. 
[35] Cockerill, P.N., Goodwin, G.H., Cary, P.D., 
Turner, C. and Johns, E.W. (1983) Biochim. Bio- 
phys. Acta 745, 70-81. 
[36] Pan, L.-X., Haritos, A.A., Wideman, J., 
Komiyama, T., Chang, M., Stein, S., Salvin, S.B. 
and Horecker, B.L. (1986) Arch. Biochem. Bio- 
phys. 250, 197-201. 
112 
